Welcome to our dedicated page for Medexus Pharmace news (Ticker: MEDXF), a resource for investors and traders seeking the latest updates and insights on Medexus Pharmace stock.
Medexus Pharmace (MEDXF) is a North American specialty pharmaceutical leader focused on innovative therapies for complex conditions in oncology, hematology, and rheumatology. This page provides investors and healthcare professionals with essential updates on the company's latest developments.
Access timely press releases covering regulatory milestones, product launches, financial results, and strategic partnerships. Our curated news collection helps stakeholders track MEDXF's progress in commercializing treatments for rare diseases and autoimmune disorders.
Key updates include FDA/Health Canada submissions, licensing agreements, clinical trial developments, and market expansion initiatives. All content is verified for accuracy and relevance to support informed decision-making.
Bookmark this page for direct access to MEDXF's official announcements and analysis of its growing role in specialty pharmaceuticals. Check regularly for updates demonstrating the company's commitment to addressing unmet medical needs through targeted therapeutic solutions.
Medexus (OTCQX: MEDXF / TSX: MDP) announced a normal course issuer bid (NCIB) accepted by the Toronto Stock Exchange, allowing purchases of up to 2,983,650 common shares, approximately 10% of the public float. As of November 12, 2025 there were 32,420,060 shares outstanding and a public float of 29,836,506. Purchases may begin on November 24, 2025 and run through November 23, 2026, will be funded from the company's general funds, executed on the TSX or alternative Canadian trading systems, and any shares purchased will be cancelled. The six‑month ADTV to October 31, 2025 was 40,066, limiting daily purchases to 10,016 shares under TSX rules, excluding block purchase exceptions.
Medexus (OTCQX: MEDXF) entered a new senior secured credit agreement with National Bank of Canada providing a US$21.0 million term loan and a US$5.0 million revolving loan, plus a US$10.0 million delayed draw feature and a US$15.0 million uncommitted accordion. The facilities mature on November 17, 2029. Medexus used net proceeds to repay existing senior secured facilities due March 2026. Borrowings bear adjusted term SOFR (or other base rate) plus a quarterly margin tied to consolidated net leverage; the initial weighted average interest rate is 6.74% versus the prior 6.95%. Medexus also intends to seek TSX approval for an NCIB to buy up to 10% of its public float over 12 months.
Medexus (OTCQX: MEDXF) reported fiscal Q2 2026 results for the period ended September 30, 2025, driven by early commercial traction for GRAFAPEX (treosulfan). Net revenue was $24.7M for the quarter and $49.4M year-to-date, down 6.1% and 7.8% YoY respectively. Medexus recorded product-level GRAFAPEX net revenue of $3.1M (Q2) and $6.2M (YTD) against ~$3.0M and $6.0M of launch investments. Adjusted EBITDA was $4.4M (Q2) and $7.8M (YTD). Available liquidity was $9.4M at Sept 30, 2025, after $16.6M principal repayments since March 31, 2025.
Medexus Pharmaceuticals (OTCQX: MEDXF) will hold a conference call at 8:00 AM ET on Thursday, November 13, 2025 to discuss results for the second fiscal quarter ended September 30, 2025. The company expects to file its financial statements and MD&A after markets close on November 12, 2025.
Live dial-in numbers are provided for Canadian/U.S. and international callers with Access Code 988000. A live webcast will be available on the Investors section of Medexus's website and a replay will be available by phone and online through Friday, November 13, 2026.
Medexus Pharmaceuticals (OTCQX:MEDXF) successfully conducted its virtual annual shareholders meeting, where all proposed directors were elected for the upcoming term. The shareholders demonstrated strong support for the board nominees, with approval ratings ranging from 92.19% to 96.45%.
Additionally, shareholders overwhelmingly approved the appointment of PricewaterhouseCoopers LLP as the company's auditors with 99.51% of votes in favor. The voting results will be filed with Canadian securities regulatory authorities.
Medexus Pharmaceuticals (OTCQX:MEDXF) reported fiscal Q1 2026 results, featuring $24.6 million in net revenue and $0.5 million in net income. The quarter highlighted the successful launch of GRAFAPEX, generating $3.0 million in product-level revenue. The company achieved $3.4 million in Adjusted EBITDA and $3.9 million in operating cash flow.
GRAFAPEX's launch shows promising momentum with 9 large commercial payers covering approximately 48 million patient lives, and 36 transplant centers representing 24% of total allo-HSCT procedures in the US already ordering the product. The company expects GRAFAPEX to be cash flow accretive by fiscal Q3 2026 and projects annual product-level revenue to exceed $100 million within five years.
The company reduced its total debt by $15.5 million to $22.0 million as of June 30, 2025, while maintaining $9.3 million in available liquidity.
Medexus Pharmaceuticals (OTCQX:MEDXF) has scheduled its first fiscal quarter 2026 earnings conference call for August 13, 2025, at 8:00 am Eastern Time. The company will release its financial results and MD&A for the quarter ended June 30, 2025, after market close on August 12, 2025.
Additionally, Medexus management will participate in two upcoming investor conferences: Cannacord Genuity's 45th Annual Growth Conference in Boston (August 12-14, 2025) and the LD Micro Main Event in San Diego (October 19-21, 2025).
Medexus Pharmaceuticals (OTCQX: MEDXF) has secured CMS approval for New Technology Add-On Payment (NTAP) reimbursement for GRAFAPEX (treosulfan) for Injection in fiscal year 2026. Starting October 1, 2025, eligible procedures will receive up to $21,411 in additional reimbursement through the NTAP program.
The approval marks a significant milestone, as GRAFAPEX was one of only five approvals out of 13 applications under the traditional pathway. Since its US commercial launch in February 2025, GRAFAPEX has gained positive formulary inclusion from 9 large commercial payers covering approximately 48 million patient lives, and 14 healthcare institutions. Additionally, 37 transplant centers have ordered GRAFAPEX, demonstrating strong initial institutional uptake.
Medexus Pharmaceuticals (OTCQX:MEDXF) reported strong fiscal year 2025 results, with revenue of $108.3 million and record net income of $2.2 million. The company achieved record Adjusted EBITDA of $20.2 million, up 3.6% year-over-year.
A key highlight was the early commercial launch of GRAFAPEX in February 2025, following FDA approval in January. Initial market response has been positive, with 34 transplant centers ordering the product and four large commercial payers covering approximately 34 million patient lives making positive formulary inclusion determinations. Medexus expects GRAFAPEX annual revenue to exceed $100 million within five years post-launch.
The company's available liquidity increased to $24.0 million as of March 31, 2025, up from $5.3 million the previous year, primarily due to a public offering of Common Shares in January 2025.
FAQ
What is the current stock price of Medexus Pharmace (MEDXF)?
What is the market cap of Medexus Pharmace (MEDXF)?
